Skip to main content

Advertisement

Table 5 Summary of emergent adverse events: safety population

From: Chondroitin sulfate efficacy versus celecoxib on knee osteoarthritis structural changes using magnetic resonance imaging: a 2-year multicentre exploratory study

  Chondroitin sulfate (n = 97) Celecoxib (n = 97) p valuea
Events n (%) Events n (%)
At least one AE 305 78 (80.4) 299 77 (79.4) >0.999
Intensity
 Mild 203 61 (62.9) 215 61 (62.9) 1.000
 Moderate 89 47 (48.5) 68 41 (42.3) 0.471
 Severe 13 9 (9.3) 16 10 (10.3) >0.999
SAE 16 10 (10.3) 9 6 (6.2) 0.435
Relationship to study treatment
 Not related 246 67 (69.1) 241 68 (70.1) >0.999
 Uncertain 20 14 (14.4) 23 13 (13.4) >0.999
 Relatedb 39 27 (27.8) 35 24 (24.7) 0.745
AE that led to study withdrawal 13 13 (13.4) 12 11 (11.3) 0.828
Ongoingc 95 50 (51.5) 100 50 (51.5) 1.000
  1. aChi-squared test for proportions (%)
  2. bRelationship considered possible, probable, or very probable
  3. cNot resolved/recovered at the end of the study
  4. AE adverse event, SAE severe adverse event